ArticleScientific reports2025
Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bypassing Androgens: Retina-Targeted 17β-Estradiol Delivery via DHED Eye Drops Ameliorates Orchiectomy-Induced Shifts in the Male Rat Visual Cortex Proteome.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deprivation therapy (ADT) has long been the standard-of-care for metastatic, hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel (DOC) and/or androgen receptor axis-targeted therapies (ARATs) such as darolutamide (DAR), enzalutamide (ENZ), apalutamide (APA), abirateone (ABI), and rezvilutamide (REZ) has been shown to significantly improve overall survival (OS) over standard-of-care in mHSPC, including standard of care plus DOC. We indirectly compared OS and progression-free survival (PFS) of DAR+DOC+ADT against approved comparators in China using Bayesian network meta-analysis. Comparator treatment data derived from published trials (identified via Medline, EMBASE, and Cochrane Library searches) and included ENZ, APA, DOC, ABI, and REZ, each with ADT. Sensitivity analysis assumed Standard Nonsteroidal Antiandrogen (SNA)+ADT efficacy was equivalent to ADT. Fixed and random effects analyses were performed in intention-to-treat (ITT) and high-volume populations. Results were summarized using hazard ratios (HRs) relative to DAR+DOC+ADT. HRs numerically favoured DAR+DOC+ADT on all comparisons. HRs on OS (fixed effects) strongly favoured DAR+DOC+ADT against DOC+ADT (0.68 [95% CrI: 0.57-0.80]), ADT (0.55 [0.44-0.67]), and SNA+ADT (0.44 [0.28-0.70]) in ITT population; similar results were observed in high-volume population in addition to APA+ADT (0.69 [0.50-0.96]). Excluding the comparison against ABI+ADT (ITT population; random effects), which was not statistically significant, HRs on PFS strongly favoured DAR+DOC+ADT on all comparisons. Outcome definition on PFS varied across trials and is a limitation in mHSPC comparisons. Results numerically favoured DAR+DOC+ADT on OS and PFS across all comparisons, with strong evidence against APA+ADT (in the high-volume population only), DOC+ADT, ADT, and SNA+ADT on OS and all comparators on PFS (excluding ABI+ADT in ITT). Findings support the continued use of DAR+DOC+ADT as frontline treatment in mHSPC, particularly in China where REZ is approved.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.